The immunology of Leishmania/HIV co-infection

Immunologic Research

Volumn 56, Issue 1, 2013, Pages 163-171

  Okwor, Ifeoma ^a   Uzonna, Jude Eze ^a  

^a UNIVERSITY OF MANITOBA   (Canada)

Author keywords

Acquired immunodeficiency syndrome (AIDS); Co infection; Human immunodeficiency virus (HIV); Leishmania; Leishmaniasis; Reactivation leishmaniasis

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 15; INTERLEUKIN 18; INTERLEUKIN 4; INTERLEUKIN 5; LIPOPHOSPHOGLYCAN;

ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; DISEASE ASSOCIATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOPATHOGENESIS; INCIDENCE; LEISHMANIASIS; MIXED INFECTION; NONHUMAN; PARASITE IMMUNITY; PREVALENCE; PRIORITY JOURNAL; SKIN LEISHMANIASIS; VIRUS IMMUNITY; VIRUS REACTIVATION; VIRUS TRANSMISSION; VISCERAL LEISHMANIASIS;

AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANIMALS; CD4-POSITIVE T-LYMPHOCYTES; COINFECTION; HIV INFECTIONS; HIV-1; HUMANS; IMMUNOSUPPRESSION; LEISHMANIA; LEISHMANIASIS;

EID: 84876415616     PISSN: 0257277X     EISSN: 15590755     Source Type: Journal    
DOI: 10.1007/s12026-013-8389-8     Document Type: Article

References (107)

1. Alvar J, et al. Leishmaniasis worldwide and global estimates of its incidence. PLoS ONE. 2012;7(5):e35671.
2. Kamhawi S. The biological and immunomodulatory properties of sand fly saliva and its role in the establishment of Leishmania infections. Microbes Infect. 2000;2(14):1765-73.
3. Molina R, Gradoni L, Alvar J. HIV and the transmission of Leishmania. Ann Trop Med Parasitol. 2003;97(Suppl 1):29-45.
4. Mougneau E, Bihl F, Glaichenhaus N. Cell biology and immunology of Leishmania. Immunol Rev. 2011;240(1):286-96.
5. Melby PC. Vaccination against cutaneous leishmaniasis: current status. Am J Clin Dermatol. 2002;3(8):557-70.
6. Scott P, et al. The development of effector and memory T cells in cutaneous leishmaniasis: the implications for vaccine development. Immunol Rev. 2004;201:318-38.
7. Bailey MS, Lockwood DN. Cutaneous leishmaniasis. Clin Dermatol. 2007;25(2):203-11.
8. WHO. HIV/AIDS Fact Sheet. 2012 cited 2012; Available from: http://www.who.int/mediacentre/factsheets/fs360/en/index.html.
9. Dougan S, et al. HIV in gay and bisexual men in the United Kingdom: 25 years of public health surveillance. Epidemiol Infect. 2008;136(2):145-56.
10. Centre for Disease Control. Kaposi's sarcoma and pneumocystis pneumonia among homosexual men- New York City and California. Morb Mortal Wkly Rep. 1981;3.
11. Hymes KB, et al. Kaposi's sarcoma in homosexual men-a report of eight cases. Lancet. 1981;2(8247):598-600.
12. Greene WC. A history of AIDS: looking back to see ahead. Eur J Immunol. 2007;37(Suppl 1):S94-102.
13. UNAIDS. Global report: UNAIDS Report on Global AIDS Epidemic. 2012.
14. Ray N, Doms RW. HIV-1 coreceptors and their inhibitors. Curr Top Microbiol Immunol. 2006;303:97-120.
15. Greene WC, Peterlin BM. Charting HIV's remarkable voyage through the cell: basic science as a passport to future therapy. Nat Med. 2002;8(7):673-80.
16. Schroder AR, et al. HIV-1 integration in the human genome favors active genes and local hotspots. Cell. 2002;110(4):521-9.
17. Garrus JE, et al. Tsg101 and the vacuolar protein sorting pathway are essential for HIV-1 budding. Cell. 2001;107(1):55-65.
18. Cruz I, et al. Leishmania/HIV co-infections in the second decade. Indian J Med Res. 2006;123(3):357-88.
19. Desjeux P, Alvar J. Leishmania/HIV co-infections: epidemiology in Europe. Ann Trop Med Parasitol. 2003;97(Suppl 1):3-15.
20. Sinha PK, et al. Liposomal amphotericin B for visceral leishmaniasis in human immunodeficiency virus-coinfected patients: 2-year treatment outcomes in Bihar, India. Clin Infect Dis. 2011;53(7):e91-8.
21. Diro A, Hailu A, Lynen L. VL-HIV co-infection in East-Africa: current challenges and perspectives. In: 7th European congress on tropical medicine and international health. Barcelona, Spain; 2011.
22. Chicharro C, Alvar J. Lower trypanosomatids in HIV/AIDS patients. Ann Trop Med Parasitol. 2003;97(Suppl 1):75-8.
23. WHO. Leishmania/HIV co-infection in south-western Europe 1990-1998: a retrospective analysis f 965 cases. Geneva: World Health Orginization; 2000. p. 14.
24. Alvar J, et al. Leishmania and human immunodeficiency virus coinfection: the first 10 years. Clin Microbiol Rev. 1997;10(2):298-319.
25. Alvar J, et al. The relationship between leishmaniasis and AIDS: the second 10 years. Clin Microbiol Rev. 2008;21(2):334-59. table of contents.
26. Alvar J, et al. AIDS and Leishmania infantum. New approaches for a new epidemiological problem. Clin Dermatol. 1996;14(5):541-6.
27. Hotez PJ, et al. Combating tropical infectious diseases: report of the Disease Control Priorities in Developing Countries Project. Clin Infect Dis. 2004;38(6):871-8.
28. Bern C, Chowdhury R. The epidemiology of visceral leishmaniasis in Bangladesh: prospects for improved control. Indian J Med Res. 2006;123(3):275-88.
29. Joshi DD, Sharma M, Bhandari S. Visceral leishmaniasis in Nepal during 1980-2006. J Commun Dis. 2006;38(2):139-48.
30. Schenkel K, et al. Visceral leishmaniasis in southeastern Nepal: a cross-sectional survey on Leishmania donovani infection and its risk factors. Trop Med Int Health. 2006;11(12):1792-9.
31. Singh SP, et al. Serious underreporting of visceral leishmaniasis through passive case reporting in Bihar, India. Trop Med Int Health. 2006;11(6):899-905.
32. UNAIDS. Global Report: UNAIDS Report on Global AIDS Epidemic. 2010.
33. UNAIDS. Global Report: UNIADS Report on Global AIDS Epidemic. 2009.
34. Singh S, et al. A new focus of visceral leishmaniasis in sub-Himalayan (Kumaon) region of northern India. J Commun Dis. 1999;31(2):73-7.
35. Gurubacharya RL, et al. Prevalence of visceral leishmania and HIV co-infection in Nepal. Indian J Med Res. 2006;123(3):473-5.
36. Guiguemde RT, et al. Leishmania major and HIV co-infection in Burkina Faso. Trans R Soc Trop Med Hyg. 2003;97(2):168-9.
37. Couppie P, et al. Comparative study of cutaneous leishmaniasis in human immunodeficiency virus (HIV)-infected patients and non-HIV-infected patients in French Guiana. Br J Dermatol. 2004;151(6):1165-71.
38. Lyons S, Veeken H, Long J. Visceral leishmaniasis and HIV in Tigray, Ethiopia. Trop Med Int Health. 2003;8(8):733-9.
39. UNAIDS/WHO. UNAIDS/WHO AIDS Epidemic Updates. 2005.
40. Ngouateu OB, et al. Clinical features and epidemiology of cutaneous leishmaniasis and Leishmania major/HIV co-infection in Cameroon: results of a large cross-sectional study. Trans R Soc Trop Med Hyg. 2012;106(3):137-42.
41. WHO. Report of the fifth consultative meeting on Leishmania/HIV coinfection, 2007: Addis Ababa, Ethiopia.
42. Daher EF, et al. Clinical and epidemiological features of visceral leishmaniasis and HIV co-infection in fifteen patients from Brazil. J Parasitol. 2009;95(3):652-5.
43. Nascimento ET, et al. The emergence of concurrent HIV-1/AIDS and visceral leishmaniasis in Northeast Brazil. Trans R Soc Trop Med Hyg. 2011;105(5):298-300.
44. Orsini M, et al. High frequency of asymptomatic Leishmania spp. infection among HIV-infected patients living in endemic areas for visceral leishmaniasis in Brazil. Trans R Soc Trop Med Hyg. 2012;106(5):283-8.
45. Lindoso JAL. Visceral Leishmaniasis - HIV co-infection: emerging in South America. In: 7th European congress on tropical medicine and international health. Barcelona, Spain: Wiley Blackwell; 2011.
46. Bernier R, et al. Activation of human immunodeficiency virus type 1 in monocytoid cells by the protozoan parasite Leishmania donovani. J Virol. 1995;69(11):7282-5.
47. Bentwich Z. Concurrent infections that rise the HIV viral load. J HIV Ther. 2003;8(3):72-5.
48. Santos-Oliveira JR, et al. High levels of T lymphocyte activation in Leishmania-HIV-1 co-infected individuals despite low HIV viral load. BMC Infect Dis. 2010;10:358.
49. Stebbing J, Gazzard B, Douek DC. Where does HIV live? N Engl J Med. 2004;350(18):1872-80.
50. Murray HW, et al. Advances in leishmaniasis. Lancet. 2005;366(9496):1561- 77.
51. Garg R, Trudel N, Tremblay MJ. Consequences of the natural propensity of Leishmania and HIV-1 to target dendritic cells. Trends Parasitol. 2007;23(7):317-24.
52. Kedzierska K, Crowe SM. The role of monocytes and macrophages in the pathogenesis of HIV-1 infection. Curr Med Chem. 2002;9(21):1893-903.
53. Azzam R, et al. Impaired complement-mediated phagocytosis by HIV type-1-infected human monocyte-derived macrophages involves a cAMP-dependent mechanism. AIDS Res Hum Retroviruses. 2006;22(7):619-29.
54. Kedzierska K, et al. Defective phagocytosis by human monocyte/macrophages following HIV-1 infection: underlying mechanisms and modulation by adjunctive cytokine therapy. J Clin Virol. 2003;26(2):247-63.
55. Barreto-de-Souza V, et al. Increased Leishmania replication in HIV-1-infected macrophages is mediated by tat protein through cyclooxygenase-2 expression and prostaglandin E2 synthesis. J Infect Dis. 2006;194(6):846-54.
56. Turco SJ. Adversarial relationship between the leishmania lipophosphoglycan and protein kinase C of host macrophages. Parasite Immunol. 1999;21(12):597-600.
57. Garg R, et al. Leishmania infantum amastigotes enhance HIV-1 production in cocultures of human dendritic cells and CD4 T cells by inducing secretion of IL-6 and TNF-alpha. PLoS Negl Trop Dis. 2009;3(5):e441.
58. Wolday D, et al. Role of Leishmania donovani and its lipophosphoglycan in CD4+ T-cell activation-induced human immunodeficiency virus replication. Infect Immun. 1999;67(10):5258-64.
59. Griffin GE, et al. Induction of NF-kappa B during monocyte differentiation is associated with activation of HIV-gene expression. Res Virol. 1991;142(2-3):233-8.
60. Bernier R, et al. The lipophosphoglycan of Leishmania donovani up-regulates HIV-1 transcription in T cells through the nuclear factor-kappaB elements. J Immunol. 1998;160(6):2881-8.
61. Wolday D, et al. Live and killed human immunodeficiency virus type-1 increases the intracellular growth of Leishmania donovani in monocyte-derived cells. Scand J Infect Dis. 1998;30(1):29-34.
62. Zhao C, et al. In primary human monocyte-derived macrophages exposed to Human immunodeficiency virus type 1, does the increased intracellular growth of Leishmania infantum rely on its enhanced uptake? J Gen Virol. 2006;87(Pt 5):1295-302.
63. Lopez-Velez R, et al. Clinicoepidemiologic characteristics, prognostic factors, and survival analysis of patients coinfected with human immunodeficiency virus and Leishmania in an area of Madrid, Spain. Am J Trop Med Hyg. 1998;58(4):436-43.
64. Bossolasco S, et al. Real-time PCR assay for clinical management of human immunodeficiency virus-infected patients with visceral leishmaniasis. J Clin Microbiol. 2003;41(11):5080-4.
65. Lindoso JA, et al. Unusual manifestations of tegumentary leishmaniasis in AIDS patients from the New World. Br J Dermatol. 2009;160(2):311-8.
66. Nylen S, Sacks D. Interleukin-10 and the pathogenesis of human visceral leishmaniasis. Trends Immunol. 2007;28(9):378-84.
67. Owens BM, et al. IL-10-producing Th1 cells and disease progression are regulated by distinct CD11c(+) cell populations during visceral leishmaniasis. PLoS Pathog. 2012;8(7):e1002827.
68. Reiner SL, Locksley RM. The regulation of immunity to Leishmania major. Annu Rev Immunol. 1995;13:151-77.
69. Afonso LC, Scott P. Immune responses associated with susceptibility of C57BL/10 mice to Leishmania amazonensis. Infect Immun. 1993;61(7):2952-9.
70. Scott P, et al. Role of cytokines and CD4+ T-cell subsets in the regulation of parasite immunity and disease. Immunol Rev. 1989;112:161-82.
71. Scott P. The role of TH1 and TH2 cells in experimental cutaneous leishmaniasis. Exp Parasitol. 1989;68(3):369-72.
72. Scharton-Kersten T, et al. IL-12 is required for natural killer cell activation and subsequent T helper 1 cell development in experimental leishmaniasis. J Immunol. 1995;154(10):5320-30.
73. Himmelrich H, et al. In BALB/c mice, IL-4 production during the initial phase of infection with Leishmania major is necessary and sufficient to instruct Th2 cell development resulting in progressive disease. J Immunol. 2000;164(9):4819-25.
74. Tripathi P, Singh V, Naik S. Immune response to leishmania: paradox rather than paradigm. FEMS Immunol Med Microbiol. 2007;51(2):229-42.
75. Wolday D, et al. HIV-1 inhibits Leishmania-induced cell proliferation but not production of interleukin-6 and tumour necrosis factor alpha. Scand J Immunol. 1994;39(4):380-6.
76. Zijlstra EE, et al. Post-kala-azar dermal leishmaniasis. Lancet Infect Dis. 2003;3(2):87-98.
77. Wolday D, et al. HIV-1 alters T helper cytokines, interleukin-12 and interleukin-18 responses to the protozoan parasite Leishmania donovani. AIDS. 2000;14(8):921-9.
78. Nigro L, et al. In vitro production of type 1 and type 2 cytokines by peripheral blood mononuclear cells from subjects coinfected with human immunodeficiency virus and Leishmania infantum. Am J Trop Med Hyg. 1999;60(1):142-5.
79. Milano S, et al. IL-15 in human visceral leishmaniasis caused by Leishmania infantum. Clin Exp Immunol. 2002;127(2):360-5.
80. d'Ettorre G, et al. Central role of interleukin-15 in human immunodeficiency virus (HIV)-infected patients with visceral leishmaniasis. Acta Trop. 2006;99(1):83-7.
81. Olivier M, et al. The pathogenesis of Leishmania/HIV co-infection: cellular and immunological mechanisms. Ann Trop Med Parasitol. 2003;97(Suppl 1):79-98.
82. Medrano FJ, et al. Dynamics of serum cytokines in patients with visceral leishmaniasis and HIV-1 co-infection. Clin Exp Immunol. 1998;114(3):403-7.
83. Villanueva JL, et al. Prospective evaluation and follow-up of European patients with visceral leishmaniasis and HIV-1 coinfection in the era of highly active antiretroviral therapy. Eur J Clin Microbiol Infect Dis. 2000;19(10):798-801.
84. Lopez-Velez R. The impact of highly active antiretroviral therapy (HAART) on visceral leishmaniasis in Spanish patients who are co-infected with HIV. Ann Trop Med Parasitol. 2003;97(Suppl 1):143-7.
85. Rosenthal E, et al. Declining incidence of visceral leishmaniasis in HIV-infected individuals in the era of highly active antiretroviral therapy. AIDS. 2001;15(9):1184-5.
86. Tortajada C, et al. Highly active antiretroviral therapy (HAART) modifies the incidence and outcome of visceral leishmaniasis in HIV-infected patients. J Acquir Immune Defic Syndr. 2002;30(3):364-6.
87. Tumbarello M, et al. Highly active antiretroviral therapy decreases the incidence of visceral leishmaniasis in HIV-infected individuals. AIDS. 2000;14(18):2948-9.
88. ter Horst R, et al. Concordant HIV infection and visceral leishmaniasis in Ethiopia: the influence of antiretroviral treatment and other factors on outcome. Clin Infect Dis. 2008;46(11):1702-9.
89. de Gaetano Donati K, et al. Effect of highly active antiretroviral therapy on the incidence of bacterial pneumonia in HIV-infected subjects. Int J Antimicrob Agents. 2000;16(3):357-60.
90. de Gaetano Donati K, et al. Impact of highly active antiretroviral therapy (HAART) on the incidence of bacterial infections in HIV-infected subjects. J Chemother. 2003;15(1):60-5.
91. Albrecht H, et al. Highly active antiretroviral therapy significantly improves the prognosis of patients with HIV-associated progressive multifocal leukoencephalopathy. AIDS. 1998;12(10):1149-54.
92. Durand I, et al. Disseminated cutaneous leishmaniasis revealing human immunodeficiency virus infection. Ann Dermatol Venereol. 1998;125(4):268-70.
93. Rueda CM, et al. HIV-induced T-cell activation/exhaustion in rectal mucosa is controlled only partially by antiretroviral treatment. PLoS ONE. 2012;7(1):e30307.
94. Aebischer T, Moody SF, Handman E. Persistence of virulent Leishmania major in murine cutaneous leishmaniasis: a possible hazard for the host. Infect Immun. 1993;61(1):220-6.
95. Aebischer T. Recurrent cutaneous leishmaniasis: a role for persistent parasites? Parasitol Today. 1994;10(1):25-8.
96. Engwerda CR, Ato M, Kaye PM. Macrophages, pathology and parasite persistence in experimental visceral leishmaniasis. Trends Parasitol. 2004;20(11):524-30.
97. Berhe N, et al. Ethiopian visceral leishmaniasis patients co-infected with human immunodeficiency virus. Trans R Soc Trop Med Hyg. 1995;89(2):205-7.
98. Berhe N, et al. HIV viral load and response to antileishmanial chemotherapy in co-infected patients. AIDS. 1999;13(14):1921-5.
99. Wolday D, et al. Emerging Leishmania/HIV co-infection in Africa. Med Microbiol Immunol. 2001;190(1-2):65-7.
100. Saravia NG, et al. Recurrent lesions in human Leishmania braziliensis infection-reactivation or reinfection? Lancet. 1990;336(8712):398-402.
101. Stenger S, et al. Reactivation of latent leishmaniasis by inhibition of inducible nitric oxide synthase. J Exp Med. 1996;183(4):1501-14.
102. Park AY, Hondowicz BD, Scott P. IL-12 is required to maintain a Th1 response during Leishmania major infection. J Immunol. 2000;165(2):896-902.
103. Cota GF, de Sousa MR, Rabello A. Predictors of visceral leishmaniasis relapse in HIV-infected patients: a systematic review. PLoS Neg Trop Dis. 2011;5(6):e1153.
104. Aebischer T, Moody SF, Handman E. Persistence of virulent Leishmania major in murine cutaneous leishmaniasis: a possible hazard for the host. Infect Immun. 1993;61(1):220-6.
105. Belkaid Y, et al. CD4+ CD25+ regulatory T cells control Leishmania major persistence and immunity. Nature. 2002;420(6915):502-7.
106. Uzonna JE, et al. Immune elimination of Leishmania major in mice: implications for immune memory, vaccination, and reactivation disease. J Immunol. 2001;167(12):6967-74.
107. Klatt NR, et al. SIV infection of rhesus macaques results in dysfunctional T- and B-cell responses to neo and recall Leishmania major vaccination. Blood. 2011;118(22):5803-12.